Jonah Feldman

Patients with advanced melanoma were treated with DOC1021, a dendritic cell vaccine.

The FDA expanded the use of the radioligand therapy to the hormone-sensitive setting in metastatic prostate cancer.

FDA advisers back RP1 plus nivolumab for anti–PD-1–refractory advanced melanoma, citing durable responses despite design concerns and awaiting confirmatory IGNYTE-3 data.

A B7-H3–targeted antibody-drug conjugate showed benefit vs chemotherapy in relapsed osteosarcoma.

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is to determine whether data from the IGNYTE trial can support an accelerated approval of RP1 plus nivolumab.

In an interview, Brian C. Betts, MD, revealed how Roswell Park Comprehensive Cancer Center achieved a dramatic increase in patient survival after allogeneic hematopoietic cell transplant.

Results of a retrospective study suggest that response to immune checkpoint inhibitors in sarcoma may be linked to other factors besides level of tumor mutational burden or mismatch repair deficiency.

An oral combination of sirolimus and domatinostat is being used to treat patients with metastatic osteosarcoma and other sarcomas.

The MonumenTAL-6 study found significant improvement with the combination of teclistamab and talquetamab vs standard regimens in relapsed/refractory multiple myeloma.

The ProstACT SELECT trial demonstrated safety and antitumor activity for TLX591-Tx in a population selected by PSMA expression in metastatic castration-resistant prostate cancer.

The FDA will review the PARP inhibitor/androgen pathway receptor inhibitor combination in metastatic castration-sensitive prostate cancer in the fourth quarter of 2026.

The ADMIRE study specifically enrolls patients with cutaneous squamous cell carcinoma who would otherwise be excluded from trials due to organ transplant or other immunocompromised state.

The ENDURANCE study showed no difference in overall survival between 2 years of lenalidomide and indefinite treatment in standard-risk patients who did not receive autologous stem cell transplant.

In an interview, Joseph Mikhael, MD, MEd, discusses the impact of the approval of subcutaneous isatuximab and its on-body delivery system in multiple myeloma.

The phase 2 OPTIMAL-e trial combines the PSMA-targeted radioligand therapy with standard ADT and ARPI in metastatic hormone-sensitive prostate cancer.

The Himalayas-1 trial will investigate rinzimetostat in combination with darolutamide in patients who previously received abiraterone for metastatic castration-resistant prostate cancer.

A phase 1 trial of the radiotherapeutic determined a recommended phase 2 dose after promising activity in heavily pretreated multiple myeloma.

Tucidinostat plus nivolumab extends progression-free survival in treatment-naive advanced melanoma, offering a promising oral, chemo-free boost to frontline immunotherapy.

Analyses of the CASSIOPEIA trial showed that some patients' outcomes could be associated with disease features besides depth of response alone.

The FDA will review the CELMoD mezigdomide in combination with carfilzomib, and dexamethasone based on the SUCCESSOR-2 trial.

A phase 1 study of actinium (²²⁵Ac) rhPSMA-10.1 injection in patients who have received prior lutetium-177 PSMA-targeted therapy has initiated dosing of patients with metastatic castration-resistant prostate cancer.

SER-155 led to short-term improvement in diarrhea management in patients receiving immune checkpoint inhibitors.

The FDA approval was based on studies using an on-body injector to administer isatuximab easily.

The PTEN IHC CDx is a companion diagnostic approved by the FDA to determine patients' eligibility for capivasertib in metastatic prostate cancer.

The FDA set a PDUFA date of April 28, 2027 for approval of the gamma secretase inhibitor for progressing desmoid tumors.

In an interview, Melody Chang, MBA, RPh, BCOP, explains the work that went into ensuring access to bispecific antibodies across a network of community oncology practices.

A Type B meeting enabled progress toward initiation of US dosing in a phase 3 trial of a radioligand antibody-drug conjugate for metastatic castration-resistant prostate cancer.

A randomized comparison of ATG, PTCy, and a combination helped characterize the similarities and differences of these regimens used as GVHD prophylaxis in stem cell transplant.

The clinicopathologic gene expression profile was granted the BDD status by the FDA for patients with T1b and T2a melanoma.

After 2 prior CRLs, the FDA accepted a resubmitted BLA as a complete class 1 response with a goal date of August 2, 2026 for the oncolytic therapy for melanoma.